342899-34-7

Basic information

• Product Name: 3-AMINO-2-CHLORO-ISONICOTINAMIDE
• Synonyms: 3-AMINO-2-CHLORO-4-PYRIDINECARBOXAMIDE;3-AMINO-2-CHLOROPYRIDINE-4-CARBOXAMIDE;3-AMINO-2-CHLORO-ISONICOTINAMIDE;3-aMino-2-carbaMoyl-2-chloro-1,2-dihydropyridine-4-carboxylic acid
• CAS NO: 342899-34-7
• Molecular Formula: C6H6ClN3O
• Molecular Weight: 171.58
• Product Categories: Amines;Pyridines
• Mol File: 342899-34-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 323.8 °C at 760 mmHg
• Flash Point: 149.6 °C
• Appearance: /
• Density: 1.484 g/cm³
• Vapor Pressure: 0.000256mmHg at 25°C
• Refractive Index: 1.654
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 14.14±0.50(Predicted)
• CAS DataBase Reference: 3-AMINO-2-CHLORO-ISONICOTINAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-2-CHLORO-ISONICOTINAMIDE(342899-34-7)
• EPA Substance Registry System: 3-AMINO-2-CHLORO-ISONICOTINAMIDE(342899-34-7)

Safety Data

• Hazardous Substances Data: 342899-34-7(Hazardous Substances Data)

Usage

General Description

3-AMINO-2-CHLORO-ISONICOTINAMIDE is a chemical compound with the formula C6H6ClN3O and a molecular weight of 169.58 g/mol. It is a derivative of isonicotinamide, a type of pyridine, and contains both an amino group and a chloro group. 3-AMINO-2-CHLORO-ISONICOTINAMIDE has been studied for its potential biological activities, including its antimicrobial and anti-tuberculosis properties. It is also used in the synthesis of other organic compounds. 3-AMINO-2-CHLORO-ISONICOTINAMIDE is typically handled and stored in accordance with standard chemical safety procedures.

InChI:InChI=1/C6H6ClN3O/c7-5-4(8)3(6(9)11)1-2-10-5/h1-2H,8H2,(H2,9,11)

Upstream product

• 64188-97-2 3-aminopyridine-4-carboxamide 
• 1453-82-3 isonicotinamide 
• 59290-91-4 3-nitroisonicotinamide 
• 173435-41-1 methyl 3-amino-2-chloropyridine-4-carboxylate 
• 58483-94-6 3-amino-2-chloroisonicotinic acid 
• 7579-20-6 3-Aminopyridine-4-carboxylic acid 

Downstream Products

• 1588951-44-3 N-{3-[4-((S)-2-amino-3-phenylpropylamino)-2-pyridin-4-ylpyrido[3,4-d]pyrimidin-8-yl]phenyl}methanesulfonamide 
• 1589082-89-2 [(S)-1-benzyl-2-(8-chloro-2-pyridin-4-ylpyrido[3,4-d]pyrimidin-4-ylamino)ethyl]carbamic acid tert-butyl ester 
• 1588951-79-4 (R)-3-phenyl-N¹-(2-pyridin-4-yl-8-pyridin-2-ylpyrido[3,4-d]pyrimidin-4-yl)propane-1,2-diamine 
• 1588951-86-3 (R)-N¹-[8-(4-methylpiperazin-1-yl)-2-pyridin-4-ylpyrido[3,4-d]pyrimidin-4-yl]-3-phenylpropane-1,2-diamine 
• 1588951-87-4 (R)-3-phenyl-N¹-(8-phenylsulfanyl-2-pyridin-4-yl-pyrido[3,4-d]pyrimidin-4-yl)propane-1,2-diamine 
• 1588951-90-9 4-(4-{[(2S)-2-amino-3-phenylpropyl]amino}-2-(pyridin-4-yl)pyrido[3,4-d]pyrimidin-8-yl)-2-methylbut-3-yn-2-ol 
• 84341-13-9 8-chloro-3H-pyrido [3 ,4-d]pyrimidin-4-one 

Relevant articles and documents

SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents

Compounds of the general formula: processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors

We report the discovery of N-substituted 4-(pyridin-2-yl)thiazole-2-amine derivatives and their subsequent optimization, guided by structure-based design, to give 8-(1H-pyrazol-3-yl)pyrido[3,4-d]pyrimidin-4(3H)-ones, a series of potent JmjC histone N-methyl lysine demethylase (KDM) inhibitors which bind to Fe(II) in the active site. Substitution from C4 of the pyrazole moiety allows access to the histone peptide substrate binding site; incorporation of a conformationally constrained 4-phenylpiperidine linker gives derivatives such as 54j and 54k which demonstrate equipotent activity versus the KDM4 (JMJD2) and KDM5 (JARID1) subfamily demethylases, selectivity over representative exemplars of the KDM2, KDM3, and KDM6 subfamilies, cellular permeability in the Caco-2 assay, and, for 54k, inhibition of H3K9Me3 and H3K4Me3 demethylation in a cell-based assay.